These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 12556354)
1. Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding. Miles PD; Barak Y; Evans RM; Olefsky JM Am J Physiol Endocrinol Metab; 2003 Mar; 284(3):E618-26. PubMed ID: 12556354 [TBL] [Abstract][Full Text] [Related]
2. Pretreatment with troglitazone decreases lethality during endotoxemia in mice. Reynolds K; Novosad B; Hoffhines A; Gipson J; Johnson J; Peters J; Gonzalez F; Gimble J; Hill M J Endotoxin Res; 2002; 8(4):307-14. PubMed ID: 12230920 [TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-alpha deficiency protects aged mice from insulin resistance induced by high-fat diet. Cha DR; Han JY; Su DM; Zhang Y; Fan X; Breyer MD; Guan Y Am J Nephrol; 2007; 27(5):479-82. PubMed ID: 17652964 [TBL] [Abstract][Full Text] [Related]
5. PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Ye JM; Iglesias MA; Watson DG; Ellis B; Wood L; Jensen PB; Sørensen RV; Larsen PJ; Cooney GJ; Wassermann K; Kraegen EW Am J Physiol Endocrinol Metab; 2003 Mar; 284(3):E531-40. PubMed ID: 12556350 [TBL] [Abstract][Full Text] [Related]
6. Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance. Todd MK; Watt MJ; Le J; Hevener AL; Turcotte LP Am J Physiol Endocrinol Metab; 2007 Feb; 292(2):E485-93. PubMed ID: 17003244 [TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies. Haluzik M; Gavrilova O; LeRoith D Endocrinology; 2004 Apr; 145(4):1662-7. PubMed ID: 14670996 [TBL] [Abstract][Full Text] [Related]
8. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Nakano R; Kurosaki E; Yoshida S; Yokono M; Shimaya A; Maruyama T; Shibasaki M Biochem Pharmacol; 2006 Jun; 72(1):42-52. PubMed ID: 16696951 [TBL] [Abstract][Full Text] [Related]
9. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Zierath JR; Ryder JW; Doebber T; Woods J; Wu M; Ventre J; Li Z; McCrary C; Berger J; Zhang B; Moller DE Endocrinology; 1998 Dec; 139(12):5034-41. PubMed ID: 9832442 [TBL] [Abstract][Full Text] [Related]
10. A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. Dhalla AK; Wong MY; Voshol PJ; Belardinelli L; Reaven GM Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1358-63. PubMed ID: 17227958 [TBL] [Abstract][Full Text] [Related]
11. PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Kintscher U; Law RE Am J Physiol Endocrinol Metab; 2005 Feb; 288(2):E287-91. PubMed ID: 15637349 [TBL] [Abstract][Full Text] [Related]
12. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway. Díaz-Delfín J; Morales M; Caelles C Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798 [TBL] [Abstract][Full Text] [Related]
17. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. Yamauchi T; Kamon J; Waki H; Murakami K; Motojima K; Komeda K; Ide T; Kubota N; Terauchi Y; Tobe K; Miki H; Tsuchida A; Akanuma Y; Nagai R; Kimura S; Kadowaki T J Biol Chem; 2001 Nov; 276(44):41245-54. PubMed ID: 11533050 [TBL] [Abstract][Full Text] [Related]
18. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells. Chung SS; Kim M; Youn BS; Lee NS; Park JW; Lee IK; Lee YS; Kim JB; Cho YM; Lee HK; Park KS Mol Cell Biol; 2009 Jan; 29(1):20-30. PubMed ID: 18936159 [TBL] [Abstract][Full Text] [Related]
19. Troglitazone and related compounds: therapeutic potential beyond diabetes. Fujiwara T; Horikoshi H Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164 [TBL] [Abstract][Full Text] [Related]
20. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Caballero AE; Saouaf R; Lim SC; Hamdy O; Abou-Elenin K; O'Connor C; Logerfo FW; Horton ES; Veves A Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]